

# SALE OF THE ONE MILLIONTH PRODUCT UNIT THROUGH CANVIEW RECORD REVENUE MONTH IN NOVEMBER OF \$10.7m

**Melbourne, Australia, 5 December 2022** – Cronos Australia Limited (ASX:CAU) (**Company**) is pleased to advise that the one millionth unit of medicinal cannabis to be sold through the Company's CanView marketplace platform has been shipped to one of the Company's 3,000+ pharmacist / prescriber customers today.

The CanView platform was launched in June 2020 and, in less than two and a half years, has sold increasing numbers of units representing quarterly compound growth of more than 40%. Nearly 215,000 units were sold during the first quarter of FY2023 alone. The Company now stocks almost 200 product lines on the CanView platform from nearly 30 leading suppliers. These products represent the majority of the medicinal cannabis products currently available in Australia.

Cronos Australia is also pleased to report that, on all financial and operational metrics, November 2022 was a record month and the second quarter of FY2023 is forecast to also be a record quarter for the Company. Key results include:

- November 2022 revenue (unaudited): \$10.7m (annualised \$128.4m)
- November 2022 Product Units sold: 86,190 (annualised 1,034,280)
- FY2023 YTD (1 July 2022 30 November 2022) revenue (unaudited): \$47.4m
- FY2023 YTD (1 July 2022 30 November 2022) Product Units sold: 379,807

Cronos Australia CEO, Rodney Cocks, said:

"With today's sale of our one millionth unit of a medicinal cannabis product through our market leading CanView platform, Cronos Australia is very proud to recognise such a significant milestone in the Company's history. Importantly, given the continued growth of unit sales, we anticipate that the second million units should be sold through the platform before the end of calendar 2023. This significant achievement could not have been realised without the efforts of the amazing Cronos Australia team.

We are also pleased to see the increasing unit sales translate into record revenues. Based on the revenues generated in November, we remain confident of our earlier forecast that our total revenues for FY2023 will exceed \$100 million, up from \$67 million in FY2022. Based on the unaudited November numbers, total revenues now annualise at nearly \$130m and unit sales at more than 1 million.

This success demonstrates the scalability of the Company's business model which we believe will continue to deliver growth and further shareholder value.

Importantly, with Cronos Australia's focus on patient care and access to medicinal cannabis, we look forward to continuing to serve our patients, prescribers, pharmacists and suppliers."

\*\* ENDS \*\*







## **About Cronos Australia Limited (ASX: CAU)**

Cronos Australia Limited is listed on the ASX (ASX: CAU).

- Cronos Australia's wholly-owned subsidiary, CDA Health Pty Ltd, operates the following businesses:
  - Burleigh Heads Cannabis BHC is a licensed wholesaler and operates a successful pharmacy, doctor and patient online portal, CanView, which facilitates the distribution of close to 200 different product SKUs within Australia from nearly 30 of the most well-known international and domestic producers
  - CDA Clinics the Group operates a successful network of clinics on the Gold Coast, Brisbane and Sunshine Coast, in addition to nationwide telehealth services
- Cronos Australia owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes face-to-face and nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- See:

www.canview.com.au www.cdaclinics.com.au www.burleighheadscannabis.com www.cannadoc.com.au

## **Authorised by**

Rodney Cocks, Chief Executive Officer and Executive Director

#### Contact

**Cronos Australia Limited** 

Rodney Cocks Chief Executive Officer and Executive Director 1300 799 491

info@cronosaustralia.com

## Media enquiries

Mark Hawthorne The Civic Partnership +61 418 999 894

mark.hawthorne@civicpartners.com.au

## Forward-looking statements

This announcement may include forward-looking statements. These forward-looking statements are based on Cronos Australia's expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Cronos Australia, which could cause actual results to differ materially from such statements. Cronos Australia makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.